NS7CAR-T Cell Therapy Inoratidza Vimbiso yeKurapa R/R T-ALL/LBL

Chinyorwa chichangobva kubuda mujenari Ropa chakaunza kutarisisa kwakakosha kune kugona kweNS7CAR-T cell therapy yekurapa yakadzokororwa kana refractory T-cell acute lymphoblastic leukemia (R/R T-ALL) uye T-cell lymphoblastic lymphoma (R/R T -LBL). Chidzidzo, chakaitwa sechikamu chekutanga chekiriniki yekuedza (ClinicalTrials.gov: NCT04572308), yakaongorora kuchengetedzwa uye kushanda kweiyi nzira yekurapa.

Muedzo wacho waisanganisira varwere vane R / R T-ALL / LBL vakagamuchira NS7CAR-T masero. Mhedzisiro yakaratidza kuti NS7CAR-T kurapwa kwaisangova kwakachengeteka asi kwakaratidza kunakidza anti-bundu chiitiko. Varwere vakarapwa neNS7CAR-T masero vakaratidza mhinduro dzakakosha dzekiriniki, zvichiratidza kugona kwekurapa uku sechishandiso chine simba kurwisa aya akaomarara.

Vatsvakurudzi vari shure kwechidzidzo ichi vanosanganisira boka renyanzvi kubva kuHebei Yanda Lu Daopei Hospital uye Hebei Senlang Biotechnology Co., Ltd. Zvavakawana zvinoratidza kuti NS7CAR-T masero anogona kugadzirwa zvakanaka pasina mamwe majeneti ekugadzirisa kudzivirira CD7 kutaura, kugadzirisa maitiro ekugadzira. uye kuwedzera kushanda kwekurapa.

Kubudirira uku muNS7CAR-T cell therapy inopindirana nekuedza kuri kuramba kuchienderera mberi kwekuvandudza marapirwo anoshanda eT-ALL uye T-LBL. Kambani yedu zvakare iri kufambira mberi mundima iyi nechigadzirwa chedu cheCAR-T, chatinotenda kuti chichazadzisa zvivimbiso zvinoonekwa neNS7CAR-T kurapwa.

Mhedzisiro inokurudzira yechidzidzo ichi inovhura nzira yekuwedzera kutsvagisa uye miedzo yekiriniki kusimbisa basa reNS7CAR-T masero mukurapa akadzokazve kana kuramba T-cell malignancies. Sezvo data rakawanda richiwanikwa, zvinotarisirwa kuti kurapwa uku kuchakurumidza kuita sarudzo yevarwere vari kurwisa zvirwere izvi.